Epizyme logo
Epizyme EPZM
report update icon

Quarterly report 2022-Q2
added 05-23-2026

Epizyme Financial Statements 2021-2010 | EPZM

Annual Financial Statements Epizyme

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Market Cap

126 M 1.11 B 1.88 B 734 M 993 M 600 M 362 M 632 M 518 M - - -

Shares

103 M 101 M 89.9 M 71.9 M 61.5 M 57.1 M 39.8 M 33 M 17 M 1.64 M 1.43 M -

Historical Prices

1.23 10.9 20.9 10.2 16.1 10.5 9.09 19.1 30.4 - - -

Net Income

-251 M -232 M -170 M -124 M -134 M -110 M -132 M -55 M -3.48 M -702 K -21 M -

Revenue

37.4 M 15.8 M 23.8 M 21.7 M 10 M 8.01 M 2.56 M 41.4 M 68.5 M 45.2 M 6.94 M -

Cost of Revenue

10.5 M 5.07 M - - - - - - - - - -

Gross Profit

- 10.7 M - - - - - - - - - -

Operating Income

-238 M -225 M -177 M -128 M -137 M -112 M -133 M -55 M -3.13 M -768 K -21 M -

Interest Expense

-22.4 M -3.97 M 1.15 M -25 K 32 K 83 K 79 K 59 K -81 K -78 K -23 K -

EBITDA

-233 M -221 M -176 M -127 M -135 M -110 M -131 M -54.3 M -2.42 M 79 K -20.5 M -

Operating Expenses

- 236 M 201 M 150 M 147 M 120 M 135 M 96.5 M 71.6 M - - -

General and Administrative Expenses

134 M 125 M 23.5 M 12.2 M 37.2 M 28.4 M 23.9 M 20.9 M 14 M 7.51 M 5 M -

All numbers in USD currency

Quarterly Income Statement Epizyme

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - 167 K 144 K 106 M 103 M 102 M 102 M 102 M 102 M 101 M 99.6 M 95.1 M 91 M 90.9 M 82.4 M 79 M 69.5 M 69.5 M 69.4 M 69.3 M 59.9 M 58.4 M 58.2 M 58 M 58 M 57.4 M 55.1 M 41.7 M 41.5 M 41.1 M 35 M 34.3 M 33.7 M 33.2 M 31 M 28.4 M 28.4 M 9.15 M 1.79 M 1.67 M 1.65 M 1.64 M 1.62 M - - - -

Net Income

- - -35.7 M -55.5 M - -65.8 M -64.4 M -70.3 M -66.2 M -56.1 M -58.5 M -50.9 M -56.4 M -36.1 M -48.5 M -29.3 M -22.9 M -37.5 M -29.1 M -34.1 M -36.2 M -37.6 M -28 M -32.5 M -35 M -24.3 M -28 M -22.9 M -22.2 M -23.1 M -25.8 M -61.3 M -15 M -19.7 M -13.4 M -6.88 M 15.9 M -9.7 M -2.21 M -7.5 M -4.54 M 4.45 M 4.86 M -5.47 M - - - -

Revenue

- - 27.5 M 8.7 M - 5.2 M 13 M 7.63 M 8.38 M 3.57 M 2.47 M 1.35 M 4.29 M 5.72 M 5.9 M 7.89 M 9.7 M 12 M 12 M - - 10 M 10 M - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - 5.17 M 2.64 M - 2 M 2.49 M 2.85 M 1.82 M 1.61 M 1.02 M 614 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - -29.8 M -50.9 M - -64.1 M -58.2 M -64.3 M -62.1 M -54.4 M -57.6 M -51.4 M -57.5 M -38 M -50.7 M -31 M -24.3 M -38.6 M -30.3 M -35 M -37.4 M -38.1 M -28.5 M -33 M -35.5 M -24.8 M -28.4 M -23.1 M -22.3 M -23.1 M -25.8 M -61.4 M -15.1 M -19.7 M -13.3 M -6.91 M 16.3 M -9.73 M -2.18 M -7.48 M -4.54 M 4.44 M 4.8 M -5.48 M - - - -

Interest Expense

- - -5.39 M -5.48 M - -5.64 M -5.58 M -5.48 M -3.97 M -1.72 M -885 K -48 K 1.15 M -15 K -13 K -6 K - -6 K -11 K 18 K - -32 K 10 K 4 K - 21 K - - - - - 20 K - 17 K 12 K 12 K - 3 K -50 K -39 K - -39 K - - - - - -

EBITDA

- - -27.2 M -49.6 M - -60.2 M -55.6 M -63.1 M -62.1 M -51.7 M -56.2 M -50.8 M -57.5 M -37.3 M -50.3 M -30.8 M -24.3 M -37.8 M -29.7 M -34.6 M -37.4 M -36.8 M -27.6 M -32.6 M -35.5 M -23.6 M -27.6 M -22.7 M -22.3 M -22 M -25.1 M -61.1 M -15.1 M -19.2 M -12.9 M -6.74 M 16.3 M -9.19 M -1.81 M -7.3 M -4.54 M 4.88 M 5.1 M -5.48 M - - - -

General and Administrative Expenses

- - 24.1 M 27.2 M - 32.8 M 33.9 M 36.4 M 35 M 30.6 M 32.7 M 26.9 M 23.5 M 17.1 M 15.7 M 12 M 12.2 M 11.5 M 10.9 M 9.36 M 8.43 M 9.31 M 11.2 M 8.27 M 7.58 M 7.52 M 7.42 M 5.85 M 6.02 M 6.68 M 5.97 M 5.24 M 4.94 M 5.67 M 5.31 M 4.96 M 4.38 M 3.59 M 3.08 M 3 M 2.33 M 1.63 M 1.64 M 1.91 M - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Epizyme EPZM
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Epizyme plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
$ 726.47 0.05 % $ 76 B usaUSA
Replimune Group Replimune Group
REPL
$ 13.15 0.61 % $ 1.22 B usaUSA
Rafael Holdings Rafael Holdings
RFL
$ 1.47 0.65 % $ 43.3 M usaUSA
REGENXBIO REGENXBIO
RGNX
$ 7.76 4.44 % $ 400 M usaUSA
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
$ 47.79 1.36 % $ 860 M usaUSA
Relay Therapeutics Relay Therapeutics
RLAY
$ 19.39 2.27 % $ 3.33 B usaUSA
Avidity Biosciences Avidity Biosciences
RNA
$ 7.97 1.66 % $ 1.1 B usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
$ 56.66 0.36 % $ 24.4 B usaUSA
Revolution Medicines Revolution Medicines
RVMD
$ 207.68 0.5 % $ 39.5 B usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 92.45 0.24 % $ 6.01 B usaUSA
Rezolute Rezolute
RZLT
$ 4.33 7.98 % $ 450 M usaUSA
Sana Biotechnology Sana Biotechnology
SANA
$ 2.88 1.21 % $ 729 M usaUSA
Seer Seer
SEER
$ 2.33 3.56 % $ 129 M usaUSA
SIGA Technologies SIGA Technologies
SIGA
$ 3.48 2.96 % $ 249 M usaUSA
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 78.95 9.65 % $ 220 M israelIsrael
Silence Therapeutics plc Silence Therapeutics plc
SLN
$ 10.14 0.78 % $ 1.44 B britainBritain
SELLAS Life Sciences Group SELLAS Life Sciences Group
SLS
$ 11.63 3.62 % $ 1.27 B usaUSA
Summit Therapeutics Summit Therapeutics
SMMT
$ 17.27 3.07 % $ 12.9 B britainBritain
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
$ 17.83 1.31 % $ 1.54 B usaUSA
Soligenix Soligenix
SNGX
$ 0.36 0.6 % $ 1.87 M usaUSA
Sanofi Sanofi
SNY
$ 39.51 1.19 % $ 48.2 B franceFrance
Spruce Biosciences Spruce Biosciences
SPRB
$ 45.42 2.1 % $ 34.8 M usaUSA
Spero Therapeutics Spero Therapeutics
SPRO
$ 1.16 4.13 % $ 65 M usaUSA
Sarepta Therapeutics Sarepta Therapeutics
SRPT
$ 17.49 0.7 % $ 1.75 B usaUSA
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 43.4 1.41 % $ 4.98 B usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
$ 25.32 0.8 % $ 1.5 B usaUSA
Sutro Biopharma Sutro Biopharma
STRO
$ 15.13 0.23 % $ 129 M usaUSA
Shattuck Labs Shattuck Labs
STTK
$ 6.5 1.04 % $ 452 M usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
$ 42.76 0.9 % $ 2.41 B usaUSA
Sesen Bio Sesen Bio
SESN
- 7.29 % $ 127 M usaUSA
Savara Savara
SVRA
$ 4.78 0.1 % $ 1.06 B usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 2.08 1.99 % $ 1.41 M chinaChina
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 17.81 0.08 % $ 28.1 B japanJapan
Protara Therapeutics Protara Therapeutics
TARA
$ 2.63 0.36 % $ 113 M usaUSA
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
$ 74.46 1.99 % $ 3.11 B usaUSA
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 72.58 0.25 % $ 11.3 B usaUSA
Tenax Therapeutics Tenax Therapeutics
TENX
$ 1.96 2.59 % $ 76.9 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 39.66 0.33 % $ 45.4 B israelIsrael
TG Therapeutics TG Therapeutics
TGTX
$ 53.91 0.12 % $ 7.78 B usaUSA
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
$ 8.07 0.54 % $ 68.7 M usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 13.72 0.99 % $ 1.85 B usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
$ 4.49 0.11 % $ 1.44 B usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
$ 42.78 3.33 % $ 2.06 B israelIsrael
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 536.4 0.37 % $ 23.8 B usaUSA
Vericel Corporation Vericel Corporation
VCEL
$ 41.07 2.29 % $ 2.07 B usaUSA
Veracyte Veracyte
VCYT
$ 47.67 4.06 % $ 3.75 B usaUSA
Vir Biotechnology Vir Biotechnology
VIR
$ 11.78 5.46 % $ 1.63 B usaUSA
Viking Therapeutics Viking Therapeutics
VKTX
$ 29.28 0.36 % $ 3.3 B usaUSA
Vanda Pharmaceuticals Vanda Pharmaceuticals
VNDA
$ 4.58 0.51 % $ 270 M usaUSA
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
$ 4.31 0.21 % $ 45.9 M usaUSA